市场调查报告书
商品编码
1519972
全球生物阻抗设备市场 2024-2031Global Bioimpedance Device Market 2024-2031 |
按产品类型(单频生物阻抗设备和多频生物阻抗设备)、模式(有线生物阻抗设备和无线生物阻抗设备)和最终用户(医院、专业)生物阻抗设备市场规模、份额和趋势分析报告诊所、復健中心等)预测期(2024-2031)
预计在预测期内(2024-2031 年)生物阻抗设备市场将以 9.6% 的复合年增长率成长。使用生物阻抗装置取代辐射来确定身体成分,因为它们使用安全电流。它们更容易操作、更快、更紧凑,并且不需要培训,其中一些甚至是手持式的。许多治疗领域,如胃肠病学、慢性发炎、术后监测、运动科学等,都广泛使用生物阻抗设备。
Bioimpedance Device Market Size, Share & Trends Analysis Report by Product Type (Single-Frequency Bioimpedance Devices, and Multiple-Frequency Bioimpedance Devices), by Modality (Wired Bioimpedance Devices, and Wireless Bioimpedance Devices), and by End-Users (Hospitals, Specialty Clinics, Rehabilitation Centers, and Others) Forecast Period (2024-2031)
Bioimpedance device market is anticipated to grow at a CAGR of 9.6% during the forecast period (2024-2031). Bioimpedance devices are used instead of radiation to determine body composition, as they employ a safe electrical current. These are easier to operate, faster, more compact, and require no training some of them are even handheld. Numerous therapeutic domains, such as gastroenterology, chronic inflammation, postoperative surveillance, sports science, and many more, make extensive use of bioimpedance devices.
Market Dynamics
Growing demand for fitness and weight management gadgets
The gadgets' capacity to provide detailed information on body composition, a parameter that is becoming more and more important for weight management and fitness enthusiasts, led to their widespread adoption. The occurrence of long-term health conditions like diabetes and obesity is driving up demand. The percentage of muscle mass and body fat can be tracked non-invasively with bioimpedance analysis, which helps manage these disorders.
Rising usage of bioimpedance devices
Bioimpedance devices offer an incredibly attractive value proposition by putting the power of proactive monitoring firmly in the hands of the end-user in an era of cost-effective healthcare system solutions. Over the next years, it is anticipated that this trend and the expansion of preventative measures will further fuel the market for bioimpedance devices.
Market Segmentation
Hospitals are Projected to Emerge as the Largest Segment
Bioimpedance devices are used by doctors to conduct body composition analyses, the results of which are utilized to monitor the fluid status of critically ill patients, evaluate lung function, and provide the proper nutritional intervention. Additionally, the integration of these devices in standard hospital operations is highly promoted as they produce patient care data points with extra value.
The global bioimpedance device market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Asia-Pacific countries to invest in affordable healthcare devices.
North America Holds Major Market Share
The presence of advanced healthcare infrastructure, high healthcare expenditure, and the growing prevalence of diabetes among the population are some of the key contributors to the high share of the regional market growth. Apart from these, the presence of major hospitals that are the primary end-users of bioimpedance devices further caters to the regional market growth.
The major companies serving the global bioimpedance device market include Inbody Co., Ltd., General Electric Company, Omron Corp., Fresenius Medical Care, and ImpediMed Ltd. among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers, and acquisitions among others to stay competitive in the market. For instance, in September 2022, GlucoRx announced the first multi-sensor non-invasive glucose monitoring. The GlucoRx BioXensor uses patented radio frequency technology alongside a multiple-sensor approach to measure blood glucose levels every minute reliably, accurately, and non-invasively.